Comprehensive nutritional support
Comprehensive nutritional support has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 13, 2026: “Сomplex nutritional support in women during the menopausal transition: effects on menopausal symptoms and sexual health”.
1 paper studies it2 findingsUpdated
See all 1 papers on comprehensive nutritional support
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“21 (75%) of the 28 patients in the MG who had moderate menopausal symptoms at the beginning of the study achieved MRS values corresponding to mild or minimal symptoms.”
None of its findings points the other way.
- 1 lab in 1 country
- Human trial1
Studies in people
1 study gave comprehensive nutritional support to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases menopausal symptomsMild or minimal symptoms achieved by 75% versus 31% down: Decreases sexual dysfunctionNo signs of sexual dysfunction in 65% versus 32% | Trial30 days | 77 peopleWomen40–50 yearsMidlife adults; Moderate menopausal symptoms at baseline during the menopausal transition | Reproductive health of woman, Feb 13, 2026 |
What did studies of comprehensive nutritional support find?
2Studies of comprehensive nutritional support measured 2 outcomes: sexual dysfunction and menopausal symptoms.
Sexual dysfunction
downin humans1
1 study
Sexual dysfunction
downin humans1
Comprehensive nutritional support decreases sexual dysfunction in humans (Menopausal transition) (No signs of sexual dysfunction in 65% versus 32%).
“on the 30th day of the study, 65% women in the MG and 32% patients in the CG had no signs of sexual dysfunction.”
Human trialMenopausal transition30 daysfemalesn = 77
Reproductive health of woman
Menopausal symptoms
downin humans1
1 study
Menopausal symptoms
downin humans1
Comprehensive nutritional support decreases menopausal symptoms in humans (Moderate menopausal symptoms at baseline during the menopausal transition) (Mild or minimal symptoms achieved by 75% versus 31%).
“21 (75%) of the 28 patients in the MG who had moderate menopausal symptoms at the beginning of the study achieved MRS values corresponding to mild or minimal symptoms.”
Human trialModerate menopausal symptoms at baseline during the menopausal transition30 daysfemales
Reproductive health of woman